Pharmacyte Biotech, Inc.
SEC CIK 1157075 · PMCB · last insider filing 2026-04-02
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Weinstein Robert | Director | filed 2022 - 2026 |
| Walker Wayne Remell | Director | filed 2022 - 2026 |
| Schechter Jonathan | Director | filed 2022 - 2026 |
| Abecassis Michael M | Director | filed 2021 - 2026 |
| Silverman Joshua | Director · Interim CEO, Interim President | filed 2022 - 2026 |
| Trujillo Carlos | Director · Chief Financial Officer | filed 2021 - 2023 |
| Allen Daniel | Director | filed 2022 - 2022 |
| Farb Daniel Stuart | Director | filed 2022 - 2022 |
| Stover Jack E | Director | filed 2022 - 2022 |
| Loehr Matthias | Director | filed 2022 - 2022 |
| Waggoner Kenneth L. | Director · Chairman, CEO, Pres and GC | filed 2021 - 2021 |
| Crabtree Gerald W | Director · Chief Science Officer | filed 2021 - 2021 |
| Yuen Thomas C K | Director | filed 2021 - 2021 |
| Liquard Thomas | Director | filed 2021 - 2021 |
| Tong Raymond CF | Director | filed 2021 - 2021 |
| Schmieg Martin | Director · CEO | filed 2009 - 2009 |
| Barnes Marylew | Director · CFO and Secretary | filed 2009 - 2009 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.